Opdivo Singled Out in Government Rule Change
The suggestion of government orchestration against Ono’s immunotherapy treatment Opdivo (nivolumab) has moved a stage further with a report in the...
5.9k Views
Yomeishu Seizo (2540 JP): Murakami’s Takeunder Is Self-Financing and a Done Deal
While the offer is marginally higher than KKR's offer (the highest received in an auction), the transaction's economics favour Murakami vs...
356 Views
Hisamitsu Pharma (4530 JP): Risk/Reward as Shares Trade Through Terms
The probability of a bump is low due to no visible activism, peers not re-rating, irrevocables, several crossholders, and the minimum can be...
372 Views
Mandom (4917 JP): CVC Outbids and Outmanoeuvres KKR
The Board recommends CVC's offer due to its higher price, acceptable financing, enhanced value plan, and shorter timelines. KKR could return with a...
382 Views
Hisamitsu Pharma (4530 JP): MBO at ¥6,082 Offers A Decent Exit Opportunity
Hisamitsu Pharmaceutical Co announced MBO to go private at ¥6,082 per share. Given the fundamentals the offer price seems a decent exit...
328 Views